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MicroRNAs (miRNAs), small non-coding regulatory RNAs that regulate gene expression at
the post-transcriptional level, are master regulators of a wide array of cellular processes.
Altered miRNA expression could be a determinant of disease development and/or pro-
gression and manipulation of miRNA expression represents a potential avenue of therapy.
Exosomes are cell-derived extracellular vesicles that promote cell–cell communication and
immunoregulatory functions.These “bioactive vesicles” shuttle various molecules, includ-
ing miRNAs, to recipient cells. Inappropriate release of miRNAs from exosomes may cause
signiﬁcant alterations in biological pathways that affect disease development, supporting
the concept that miRNA-containing exosomes could serve as targeted therapies for par-
ticular diseases. This review brieﬂy summarizes recent advances in the biology, function,
and therapeutic potential of exosomal miRNAs.
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INTRODUCTION
Exosomes are small (30–90 nm) extracellular vesicles derived from
the multivesicular body (MVB) sorting pathway. These vesicles
are produced by a wide variety of cell types including reticulo-
cytes, epithelial cells, neurons, and tumor cells (Thery et al., 2009).
Exosomes have been isolated from bronchoalveolar lavage, urine,
serum, bile, and breast milk (Thery, 2011). Although previously
considered to be cellular waste products (Thery, 2011), recent
studies have demonstrated that exosomes are “bioactive vesicles”
that promote intercellular communication and immunoregula-
tory processes by shuttling molecules between cells (Thery et al.,
2009; Pegtel et al., 2010).
One of the most recent exciting ﬁndings is that microRNAs
(miRNAs) exist in exosomes and these exosomal miRNAs can
be functionally delivered to target cells (Montecalvo et al., 2012).
miRNAs are small non-coding regulatory RNAs that bind to com-
plementary sequences in the 3′-untranslated region (3′UTR) of
target mRNAs, leading to either translational repression or target
degradation of the speciﬁc mRNA (Bartel, 2004, 2009). miR-
NAs play a pivotal regulatory role in diverse biological processes
including but not limited to, development and cell signaling, pro-
liferation and differentiation (Bartel, 2004, 2009). While miRNA
expression patterns are incompletely deﬁned in most cell types
under normal conditions, aberrant expression of certain miR-
NAs has been described in diverse human diseases, suggesting
that miRNAs can be used as biomarkers for disease develop-
ment and as a potential target of therapy (Jiang et al., 2009).
Several publicly available databases (e.g., miR2Disease) have been
established which document the relationships between the expres-
sion of speciﬁc miRNAs and the development and/or progression
of speciﬁc human diseases (Jiang et al., 2009). Identiﬁcation of
miRNAs key to disease pathogenesis provides new insights into
the development of therapeutic targets in the treatment of human
diseases, particularly for some forms of cancer. Currently, sev-
eral approaches to manipulate miRNA function are being studied
in clinical trials (Kasinski and Slack, 2011). Because inappropri-
ately released miRNA-containing exosomes have been shown to
signiﬁcantly alter biological pathways integral to disease devel-
opment (Record et al., 2011), it is postulated that exosomes
could be used to deliver therapeutic molecules in a variety of
human diseases. Here, we brieﬂy summarize recent advances
in the biology, function and therapeutic potential of exosomal
miRNAs.
EXOSOMES ARE CELL–CELL MEDIATORS WITH
PHYSIOLOGICAL AND PATHOLOGICAL SIGNIFICANCE
Exosomes are the newest family member of “bioactive vesi-
cles.” These bioactive vesicles were originally described during
maturation of reticulocytes into erythrocytes. These small vesi-
cles contained the transferrin receptor which is downregulated
in mature erythrocytes (Pan and Johnstone, 1983). Exosomes
are also secreted by a variety of cell types including mast cells
(Laulagnier et al., 2004), B lymphocyte cell lines, dendritic cells
(Laulagnier et al., 2004), platelets, astrocytes, neurons, and epithe-
lial cells (Hogan et al., 2009; Zhou et al., 2011). Exosomes enter
the circulatory system and bodily ﬂuids and have been detected
in plasma, bronchoalveolar lavage, blood, urine, bile (Masyuk
et al., 2010), ascites (Rupp et al., 2011), breast milk, and cere-
brospinal ﬂuid. Tumor-derived exosomes have been identiﬁed
in the plasma of patients with lung adenocarcinoma, glioblas-
toma multiforme, malignant glioma, and ovarian carcinoma
ascites (Skog et al., 2008; Rabinowits et al., 2009; Rupp et al.,
2011).
The formation and release of exosomes are tightly regulated
processes governed by multiple signaling mechanisms. Various
stimuli inﬂuence exosome secretion including activation of a
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variety of receptors including the P2X receptor by ATP on mono-
cytes and neutrophils, the thrombin receptor on platelets, and
toll-like receptor-4 (TLR-4) by bacterial lipopolysaccharide (LPS)
on dendritic cells (Bhatnagar and Schorey, 2007). Morphological
studies suggest that exosomes are derived from the MVB sort-
ing pathway. The MVBs fuse with the plasma membrane and
release the vesicles into the extracellular milieu as exosomes.
The exosomes consist of a lipid bilayer membrane surround-
ing a small cytosol that lacks cellular organelles such as mito-
chondria, lysosomes, endoplasmic reticulum, nucleus, and Golgi
apparatus.
The formation and release of exosomes involves contrac-
tile machinery that draws opposing membranes together before
pinching off the membrane connection and releasing the vesi-
cle into the extracellular space (Cocucci et al., 2009). SNARE
(soluble NSF attachment protein receptor) complexes are pro-
posed to be involved in bringing the membranes together in
opposition, as there is an energy requirement for the membrane
fusion process (Sudhof and Rothman, 2009). SNAREs can be
divided into vesicle (v-SNAREs) and target SNARES (t-SNAREs;
Fukuda et al., 2000). The complex begins assembling at the N-
terminal region of the SNARE motifs and proceeds toward the
C-termini which anchors the interacting proteins in the mem-
branes (Sutton et al., 1998). An intermediate complex composed
of SNAP-25 and syntaxin-1, which interacts with synaptobrevin-
2 then forms. Recent studies from Thery’s group demonstrated
that several Rab family proteins, including Rab27a and Rab27b,
are key regulators of the exosome secretion pathway (Ostrowski
et al., 2010). Several lines of evidence support a role for Rab27a
and Rab27b in MVB docking at the plasma membrane. Rab27a
silencing increases the size of MVBs; alternatively, Rab27b silenc-
ing results in redistribution of the MVBs to the perinuclear region
(Ostrowski et al., 2010). Another Rab family member protein,
Rab35, is a target of TBC1D10A-C, which regulates exosome
secretion and inhibiting Rab35 activity induces intracellular accu-
mulation of endosomal vesicles and impaired exosome secretion
(Hsu et al., 2010). Recent studies revealed that exosomes can be
released into the extracellular environment by the outward bud-
ding and ﬁssion of the plasma membrane, a pathway called the
exosome and microvesicle (EMV) budding pathway. The pro-
gression of the EMV pathway is regulated by multiple processes
including the elevation of intracellular calcium and reorganiza-
tion of the cell’s structural scaffolding. The current model of
exosome formation and release of exosomes is diagrammed in
Figure 1.
Exosomes released from donor cells can be taken up by recip-
ient cells, where an array of biological processes can be impacted
in the recipient cells, including cell proliferation and differen-
tiation, apoptosis, and the immune response (Abusamra et al.,
2005; Yu et al., 2007). Exosomes have been implicated as media-
tors in the communication between T cells and antigen-presenting
cells (APCs) at the immune synapse. Professional APCs secrete
major histocompatibility complex class II (MHC II) carrying
exosomes (Buschow et al., 2010), and these exosomes can stim-
ulate antigen-speciﬁc MHC class II-restricted T cell responses
(Raposo et al., 1996). Intestinal epithelial cell-derived exosomes
containing αvβ6 integrin and food antigen induced dendritic cell
FIGURE 1 | Exosome biogenesis and release. Exosomes are derived from
the multivesicular bodies (MVBs) which are known as late endosomes.
Extracellular stimuli (e.g., microbial infection) can induce exosome
formation and trigger exosome release. The exosomes can be released into
the extracellular environment by either fusion of MVBs with the cell surface
(1) or budding pathway (2). Fusion of MVBs with the plasma membrane
surface involves the SNARE protein complex that brings the two
membranes together. Budding exosomes are released from cytoplasm by
budding of cell plasma membrane in response to cell stimulation.
tolerance and tolerogenic DCs in a model of tolerance induction.
In addition, the presence of these intestinal epithelial cell-derived
exosomes alsoimpacted the development of antigen-speciﬁc T
regulatory cells (Chen et al., 2011). Additional normal cellular
processes inﬂuenced by exosomal contents include myelin mem-
brane biogenesis and neuronal plasticity (Bakhti et al., 2011) in the
central nervous system (CNS) and decreasing cholangiocyte pro-
liferation via interactions with cholangiocyte cilia (Masyuk et al.,
2010).
Exosomes may also be involved in pathogenic processes. Extra-
cellular amyoid ﬁbril formation, a key feature of Alzheimer’s
disease, occurs at an accelerated rate in the presence of GM1
ganglioside-containing exosomes (Yuyama et al., 2008). These data
suggest that targetingGM1 in exosomesmay provide amechanism
to slow the rate of plaque formation. Tumor-derived exosomes
may also signiﬁcantly inﬂuence the development and effectiveness
of anti-tumor immune responses (Rupp et al., 2011). Exposure
of peripherial blood mononuclear cells (PBMCs) to exosomes
isolated from ascites of ovarian cancer patients impaired the cyto-
toxic activity of the PBMCs in the presence of dendritic cells. In
addition to containing tumor antigens, exosomes secreted from
cancer cells also have been shown to contain two molecules criti-
cal to immunoregulation, PD-L1 and FasL. The presence of FasL
and TRAIL in exosomes may contribute to apoptosis of cells of
the immune response, thereby serving as a mechanism of tumor
escape from immunosurveillance (Peng et al., 2011). For exam-
ple, exosomes from plasma of cancer patients have been shown to
induceT cell apoptosis (Ichimet al., 2008), reminiscent of Fas-FasL
counterattack that has been described in some cancers (Alderson
et al., 1995; O’Connell et al., 1998). Intercellular communication
via exosomes is not limited to communications between mam-
malian cells. Interestingly, exosomes have been isolated from the
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protozoan parasite, Leishmania, and these exosomes deliver pro-
tozoan proteins to macrophages in the vertebrate host. Similar to
what is observed with mammalian-derived exosomes, protozoan
exosomes may inﬂuence the host immune response and regulate
cell signaling pathways (Silverman et al., 2010). Exosomes can
also transport pathogen or virus proteins to neighboring and/or
distant cells and enhance disease spread (Schorey and Bhatna-
gar, 2008). The infectious form of the prion protein, PrPsc, has
been found in exosomes. Exosomally derived PrPsc is infectious to
mice (Vella et al., 2007). This ﬁnding suggests that in humans
or wildlife, exosomally derived PrPSc could serve as a source
of infectious material in the host which accelerates the spread
of the misfolded protein through the body. Also, because exo-
somes are in mucus, urine, and blood, disease spread between
hosts may be enhanced by the presence of PrPSc-containing
exosomes.
Exosomes are considered extracellular organelles which can
affect neighboring cells following delivery of their contents into
target cells (Silverman and Reiner, 2011). It has been speculated
that the composition of exosomes is quite heterogenic, depend-
ing on the cellular origin of the exosome. Large-scale proteomics
and phosphoproteomics studies of exosomes derived from var-
ious cell types suggest that the exosomes shuttle wide array of
biologically relevant molecules, including lipids, carbohydrates,
RNAs, and proteins (Schorey and Bhatnagar, 2008), as outlined in
Figure 2. Detailed information regarding the contents of exosomes
is available (http://dir.nhlbi.nih.gov/papers/lkem/exosome). The
contents of urinary exosomes have been characterized by Knep-
per’s group. This study identiﬁed 1132 proteins contained within
the exosomes. In addition, phosphoproteomic studies identiﬁed
several unique phosphorylation sites (Gonzales et al., 2009). This
study, along with others, support the potential for exosomes
obtained from bodily ﬂuids to serve as biomarkers of disease
development and/or progression.
MicroRNAs ARE GENE REGULATORS AND IMPORTANT
BIOMARKERS WITH THERAPEUTIC POTENTIAL
To date, over 1000 human miRNAs have been identiﬁed and it is
predicted that miRNAs control the expression of approximately
60% of all human genes (Bentwich et al., 2005; Krol et al., 2010).
Accumulating data indicate that miRNAs comprise an essential
component in the complex regulatory networks controlling a
wide array of cellular processes, including the timing of devel-
opmental processes, cell proliferation/differentiation, apoptosis,
organ development (Tiscornia and Izpisua Belmonte, 2010), and
immune regulation (O’Neill et al., 2011; Zhou et al., 2011). Sev-
eral excellent reviews have been recently published on these topics
(O’Neill et al., 2011; Zhou et al., 2011).
FIGURE 2 | Composition of exosomes. Exosomes carry a wide array of
molecules including proteins, DNAs, mRNAs, and miRNAs, depending on a
variety of factors including the cell type from which the exosome originates,
the state of health of the host, and extracellular stimuli. The contents of
exosomes can be transferred from origin cells to target cells, resulting in an
elaborate intercellular communication network. Exosomal miRNAs conﬁrmed
by different methods (e.g., microarray and qPCR) under different pathological
conditions are listed in this ﬁgure. For details, also seeTable 1.
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Aberrant miRNA expression has been linked to the initiation
and progression of certain cancers (Mencia et al., 2009). An exam-
ple of a miRNA associated with cancer development (that is, an
oncogenic miRNA or oncomiR) is miR-21. miRNA-21 targets
tumor suppressor genes and upregulation of miR-21 is associated
with a wide variety of cancers including breast, ovaries, cervix,
colon, lung, liver, brain, esophagus, prostate, pancreas, and thy-
roid cancers (Volinia et al., 2006; Lui et al., 2007). miRNAs are
also involved in developmental processes in vertebrates. Studies
utilizing genetically modiﬁed mice have demonstrated the critical
requirement formiRNAs in cardiac development, asmice deﬁcient
in Dicer experience cardiac failure (Chen et al., 2008). In the CNS,
the role of miRNAs in regulating neuronal development, plas-
ticity and differentiation is under exploration (Guo et al., 2002;
Gao et al., 2010). In Parkinson’s disease, miR-34b and miR-34c
are decreased and this decrease in expression is accompanied by
a decrease in cell viability of dopaminergic neurons (Minones-
Moyano et al., 2011). InHuntington’s disease, bothmurinemodels
of the disease as well as human tissue samples have demonstrated
that RE1 silencing transcription (REST) factor, a transcriptional
repressor, is not appropriately expressed, and can be found in the
nucleus of neurons rather than the cytoplasm. REST dysregulation
results in a wide array of miRNAs are repressed, thereby resulting
in an overexpression of mRNAs in the CNS of individuals with
Huntington’s disease (Johnson et al., 2008; Buckley et al., 2010).
The small size (23–24 nucleotides in length) of mature miRNA
molecules makes them very attractive targets for drug develop-
ment. It may be possible to restore normal levels of mature forms
of dysregulated miRNAs in disease states and provide therapeutic
beneﬁts to the host by appropriately regulating the level of expres-
sion of their target genes. A variety of delivery approaches have
been used to deliver miRNA precursors into cells to overexpress
miRNAs of interest in vitro (Hu et al., 2009; Kota et al., 2009).
In vivo studies have been performed in mice to test the therapeutic
potential of miRNAs. Intranasal administration of cholesterol-
conjugated anti-miR-126 to the asthmaticmice resulted in reduced
airwaydisease characterized bydecreasedT-helper-2 cytokine pro-
duction,decreased airwayhyperresponsiveness andmuscus hyper-
secretion, and a reduction in airway-inﬁltrating eosinophils and
neutrophils compared to control-treated asthmatic mice (Mattes
et al., 2009). Other means of delivery of antisense miRNAs has also
been successful. Inhibition of miR-122 by systemic administration
of amiR-122 antisense oligonucleotide reduced plasma cholesterol
levels and decreased hepatic fatty acid and cholesterol synthesis
rates in normal mice. Therapeutic administration of anti-miR-122
also reduced levels of triglycerides and improved hepatic steato-
sis in diet-induced obese mice (Esau et al., 2006). Mice appeared
healthy after one month of antisense therapy. The lack of obvious
toxicity further cements the potential of miRNAs as therapeutic
molecules.
The potential for use of miRNAs against cancer has been exten-
sively studied. A recent study using plasmid-expressed miR-155 in
nasopharyngeal carcinoma cells demonstrated decreased expres-
sion of manganese superoxide dismutase in miR-155 overexpress-
ing CNE1 cells and reduced resistance to ionizing radiation (Du
et al., 2011). In vivo administration of a lentivirus-expressing miR-
26a resulted in inhibited tumorigenicity of nasopharyngeal cells in
nude mice (Lu et al., 2011). Systemic delivery of synthetic miR-16
reduced the growth of metastatic prostate tumors by downregulat-
ing multiple cell-cycle genes in a prostate cancer xenograft model
(Takeshita et al., 2010). Let-7 miRNAs are proposed to function
as tumor suppressors by negatively regulating multiple oncogenes
(RAS,MYC,HMGA2) and cell-cycle promoters (CDC25A,CDK6,
CCND2; Johnson et al., 2005; Mayr et al., 2007). Administration
of let-7 miRNA prevented tumor formation in a mouse model
of non-small cell lung cancer (Kumar et al., 2008). Intratumoral
injection of synthetic let-7b miRNA signiﬁcantly reduced tumor
growth, induced necrotic cores in the tumors, and reduced NRAS
and CDK6 expression in tumors in a mouse model of lung cancer
(Trang et al., 2010). Such approaches to manipulate the expres-
sion of miRNA targets in the context of disease are currently being
explored in clinical trials (Kasinski and Slack, 2011).
EXOSOMAL SHUTTLE miRNAs
A recent breakthrough in exosome biology is that RNA mole-
cules, in particular, miRNAs, are present in these vesicles. To date,
studies have demonstrated that miRNAs in exosomes can inﬂu-
ence target cell function (Kosaka et al., 2010; Mittelbrunn et al.,
2011). Hunter et al. (2008) identiﬁed miRNAs expressed in circu-
lating plasma microvesicles from normal subjects, providing the
basis for future work examining the predictive role of peripheral
blood miRNA signatures in human disease, as well as deﬁning
the biological processes regulated by particular miRNAs. Koh et
al. demonstrated that miRNAs are also found in the extracellular
environment of human embryonic stem cell-derived mesenchy-
mal stem cells (hES-MSC). Signiﬁcant differences in expression
proﬁle of miRNAs in the intracellular and extracellular environ-
ment of hES-MSC cultures were identiﬁed. Interestingly, the let-7
miRNA family is highly expressed in both intra- and extra-cellular
samples of hES-MSC (Koh et al., 2010). Advances in miRNA array
techniques have provided signiﬁcant advances in miRNA proﬁl-
ing of exosomes. Exosomes contain a substantial amount of small
RNAs, but little or no ribosomal RNA compared to the levels
observed in the donor cells (Valadi et al., 2007). Moreover, selec-
tive packaging of miRNAs into exosomes appears to occur, as the
miRNA proﬁles in exosomes do not reﬂect the miRNA proﬁles
observed in the parental cells (Valadi et al., 2007; Skog et al., 2008;
Taylor and Gercel-Taylor, 2008; Rabinowits et al., 2009; Mittel-
brunn et al., 2011). Exosomes isolated from T cells, B cells, and
dendritic cells had miRNA expression proﬁles unique from their
parent cells. The authors also demonstrated that therewas antigen-
driven unidirectional transfer of miRNAs from the T cell to the
APCmediated byCD63+ exosomes (Mittelbrunn et al., 2011). The
mechanism for the selective packaging of RNAs into exosomes is
unclear. Compared to cellular RNAs, exosomal RNAs aremore sta-
ble (Keller et al., 2011), and are reportedly resistant to degradation
during prolonged storage and freeze/thaw cycles (Reid et al., 2011).
The stability of the contents of these membrane-bound structures
adds to the attractiveness of exosomes as biomarkers of cancer and
other diseases.
Exosomal miRNAs have been implicated in many of exosome-
mediated biological functions (Wang et al., 2010). Exosomes
derived from a human (HMC-1) and mouse (MC/9) mast cell
lines transport RNA to neighboring mast cells, impacting the
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function of the recipient mast cells (Valadi et al., 2007; Schorey and
Bhatnagar, 2008). Impairment of exosome production reduces
the transfer of miRNAs to APCs. The miRNAs transferred at the
immune synapse are functional and can alter gene expression in
the recipientAPCs (Mittelbrunn et al., 2011). Together, the current
data make a strong case for role of exosomally-derived miRNAs as
mediators of cell function.
EXOSOMAL miRNAs AS BIOMARKERS OF DISEASE
Aberrant expression of miRNAs has been identiﬁed in numerous
diseases (Table 1). In addition, exosomal miRNAs are consid-
ered as biomarkers for many pathological states (Michael et al.,
2010; Ciesla et al., 2011). Exosomes from diseased individuals
contain miRNAs not found in normal, healthy subjects (Taylor
and Gercel-Taylor, 2008; Rabinowits et al., 2009). Many miR-
NAs, including virus miRNAs, are in exosomes. Nevertheless, it
is unknown how exosomal miRNAs function in the recipient cells.
Exosomes released from Epstein–Barr virus (EBV)-infected B95-
8 LCL cells were identiﬁed in monocyte-derived dendritic cells,
resulting in gene silencing in recipient cells (Pegtel et al., 2010).
Furthermore, exosomal-loaded viral miRNAs suggest that exo-
some may serve as a vesicle to contribute to disease spread or
pathogenesis (Meckes et al., 2010; Pegtel et al., 2011). Interest-
ingly, macrophages have been shown to inﬂuence the invasive-
ness of breast cancer cells through exosome-mediated delivery of
oncogenic miRNAs from the macrophages to the cancerous cells
(Yang et al., 2011). Exosomes released from dendritic cells can
fuse with the target dendritic cells and release their contents into
the target cells, resulting in mRNA silencing (Montecalvo et al.,
2012). A recent report from the Lim group demonstrated that
miRNA-containing stroma-derived exosomes contribute to B cell
quiescence. The transfer of miRNAs from bone marrow stroma to
B cells may participate in dormancy of bone marrow metastases
(Lim et al., 2011).
The levels of speciﬁc miRNAs in certain disease states may
provide insight into disease pathogenesis and/or potential mech-
anisms of repair. miR-133a levels are elevated in circulating exo-
somes derived from injured myocardium in patients with cardio-
vascular diseases (Kuwabara et al., 2011). In addition, miR-133a
is implicated to regulate NFATc4, a protein that contributes to
cardiac hypertrophy (Li et al., 2010). Treatment with miR-133a
inhibitors reduced the level of cardiac hypertrophy (Li et al.,
2010).
Exosomal miRNA proﬁles of circulating tumor exosomes are
unique from those in normal controls (Taylor and Gercel-Taylor,
2008). Because of this unique exosomal miRNA signature, screen-
ing tests utilizing circulating exosomal miRNAs as markers of dis-
easemight beused to identify tumordevelopment.UniquemiRNA
proﬁles have been described in exosomes from patients with lung
cancer, glioblastoma, and hepatocellular carcinoma (Rabinowits
et al., 2009). In cancer, a variety of processes are impacted by exo-
somal miRNAs. While in cases such as lung adenocarcinoma, the
miRNA signatures are different between cancer patients and nor-
mal controls, the exosome-loaded miRNAs are similar in nature
to the miRNAs isolated from the tumors. In the case of hepato-
cellular carcinoma, some of the miRNAs transferred by exosomes
can downregulate transforming growth factor-β activated kinase-1
(TAK1) pathway in hepatocarcinogenesis. This ﬁnding suggests
that miRNAs from the exosomes may be involved in the local
spread, intrahepatic metastases, or multifocal growth in hepa-
tocellular carcinoma (Kogure et al., 2011). Liu et al. (2010) has
demonstrated that tumor-derived exosomes are pivotal in pro-
moting tumor metastasis via a proinﬂammatory cytokine-driven
expansion of myeloid-derived suppressor cells via the MyD88
pathway. Taken together, current exosomal miRNA studies have
opened a new window for the development of biomarkers for
important human diseases.
THERAPEUTIC POTENTIAL OF TARGETING EXOSOMAL
miRNAs
Due to their ability to efﬁciently shuttle small molecules between
cells, exosomes are an extremely promising therapeutic tool for
numerous diseases. Alternatively, because of the pathogenic sig-
niﬁcance of exosomal miRNAs in an array of diseases, drug devel-
opment focusing on targeting the release of exosomal miRNA
contents has begun. The use of exosomes as therapeutic delivery
vehicles covers awide array of diseases, including but not limited to
cancer, virus-induced diseases, andparasitic diseases.Of particular
note, the Wood laboratory successfully expressed Lamp2b, an exo-
somalmembraneprotein, fused to aneuron-penetratingRVGpep-
tide in the dendritic cells isolated from mice. Exosomes released
from these cells were loaded with exogenous siRNA to GAPDH by
electroporation. Intravenously injected RVG-targeted exosomes
delivered GAPDH siRNA speciﬁcally to neurons, microglia, oligo-
dendrocytes in the brain, resulting in a speciﬁc gene knockdown
(Alvarez-Erviti et al., 2011). Akao et al. reported that chemically
modiﬁed miRNAs (i.e., miR-143BPs) are detectable in exosomes
secreted fromTHP-1macrophages followingmiR-143BP transfec-
tion. More importantly, increased miR-143BP levels were detected
in the serum, tumor, and kidney of the host animals when the mice
were intravenously injected with the THP-1 macrophages trans-
fected with miR-143BP (Akao et al., 2011). These data suggest that
manipulating exosomal miRNAs ex vivo may be an efﬁcient tool
to deliver miRNAs to target speciﬁc organs. Exosomes have also
been utilized successfully to deliver siRNAs to speciﬁc cell types
in vivo in mice (van den Boorn et al., 2011). Thus far, studies on
manipulation of exosomal miRNAs are primarily in animal mod-
els and the clinical application of this work is unclear, although it
is obvious that, (1) exosomes could serve as targets of therapy and
(2), delivery miRNAs to target cells through exosomes is feasible.
Therefore, functional manipulation of miRNAs in exosomes and
in vivo delivery of exosomal miRNAs would be novel targets for
therapeutic intervention for a variety of human diseases. With the
advance of technology that allows us to manipulate the miRNA
contents in exosomes as well as exosomal membrane proteins, the
future studies on exosomal miRNAs will beneﬁt all patients by
providing efﬁcient diagnosis and disease-speciﬁc therapy.
CONCLUSION AND PERSPECTIVES
Currently, ExoCarta (Version 3.1) contains information on 11,261
protein entries, 2375 mRNA entries, and 764 miRNA entries
that were obtained from 134 exosomal studies (Mathivanan
et al., 2011). There are several advantages for the use of
exosomes/microvesicles to deliver information to a target cell.
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Table 1 | Exosomal miRNAs as potential biomarkers and therapeutic targets
Exosomal miRNAs Pathological conditions Potential pathological significance Reference
miR-23a, 132, 181a, 215, 362-5p, 375,
513a-3p, 523
Ovarian FF from estrous mares Biomarker; oocyte growth andmaturation da Silveira et al. (2012)
miR-20b, 22, 23b, 24, 135a, 135b, 152, 181c,
197, 223, 320a, 323-5p, 378, 433
Ovarian FF from estrous mares Biomarker; oocyte growth andmaturation da Silveira et al. (2012)
miR-25, 188-5p, 192, 320b, 320c Ovarian FF from estrous mares Biomarker; oocyte growth andmaturation da Silveira et al. (2012)
miR-223 Human MDM and breast cancer cell
lines, SKBR3 and MDA-MB-231
Regulate the invasiveness of breast can-
cer cells
Yang et al. (2011)
miR-584, 517c, 378, 520f, 142-5p, 451, 518d,
215, 376a, 133b, 367
HCC Hep3B, Human HCC cell line Multiple oncogenic or tumor suppressor
genes
Kogure et al. (2011)
miR-142-5p, 15a, 129, 101, 296, 145, 361,
23b, 23a, 100, 99b, 324-5p, 30a-5p, 7, 15b,
27b, 615, 218, 328, 10a, 222, 342, 125a, 572,
149, 30d, 451, 25, let-7a, let-7c, let-7b, let-7f
Human CD105+ and CD105- renal
carcinomas cells
Angiogenic switch and coordinating
metastatic diffusion, downregulated in
CD105+ exosome
Grange et al. (2011)
miR-200c, 146a, 184, 335, 646, 449b, 650,
141, 183, 19b, 29c, 182, 19a, 92, 301, 151,
130b, 22, 186, 140, 486, 26b, 29a, let-7g
Human CD105+ and CD105− renal
carcinomas cells
Angiogenic switch and coordinating
metastatic diffusion, upregulated in
CD105+ exosome
Grange et al. (2011)
miR-1, 133a Patient, acute myocardial infarction Acute myocardial infarction Kuwabara et al. (2011)
miR-335 The human Jurkat-derivedT cell lines
J77cl20 and the lymphoblastoid B
cell lines Raji
Downregulates target gene expression in
the APC
Mittelbrunn et al. (2011)
miR-16, 27a, 146b and 222 Rat primary and differentiated
adipocytes
Lipid storage (metabolic diseases) Müller et al. (2011)
EBV miRNAs C666 cell, Human nasopharyngeal
carcinoma cells
Manipulate the tumor microenvironment
and inﬂuence neighboring cell signaling
Meckes et al. (2010)
Let-7 miRNA family AZ-P7a, Hetastatic gastric cancer
cell line
Tumorigenesis and metastasis Ohshima et al. (2010)
miR-486, 328, 183, 32, 574, 27b, 222, 197,
151, 17-5p, 199a*, 133b, 320, 96, 103
PBMC Regulate homeostasis of hematopoietic
cells and of metabolic function
Hunter et al. (2008)
miR-219, 579, 515-5p, 29c, 15b, 483-5p, 29a,
22, 23a, 16, 30d, 302c, 452, 646, 488, 181c
A549, Human lung adenocarcinoma
epithelial cell line
Cell–cell communication Wang et al. (2010)
miR-204, 219, 483-5p, 26b, 16, 30d, 22, 646,
145, 29a, 23a, 373, 199b, 342, 29a
HepG2, Human hepatocellular liver
carcinoma cell line
Cell–cell communication Wang et al. (2010)
miR-517a, 21 BeWo, Human placenta choriocarci-
noma cell line
Signal transduction Luo et al. (2009)
let-7b, let-7c*, miR-128, 150*, 17, 1908, 212,
27b*, 29b, 29c, 335, 379*, 433, 454, 483-3p,
584, 621, 652, 760, 888*
parotid saliva from Sjogren’ syn-
drome patient and normal volunteer
Biomarkers of the diagnosis and progno-
sis of various salivary gland pathologies
Michael et al. (2010)
let-7b, miR-150*, 23a*, 27b*, 29b, 29c, 335,
379*, 433, 454, 483-3p, 584, 621, 652, 760,
888*, miRPIus_17824, 17841, 17848, 17858,
17824, 17841, 17848, 17858, 42487, 42526
Parotid saliva from Sjogren’ syn-
drome patient and normal volunteer
Biomarkers of the diagnosis and progno-
sis of various salivary gland pathologies
Michael et al. (2010)
miR-16, 21, 155 HEK293, Human embryonic kidney
cell line
Signaling molecules in physiological and
pathological events; exerted gene silenc-
ing in the recipient cells
Kosaka et al. (2010)
Let-7a, miR-15b, 16, 19b, 21, 26a, 27a, 92,
93, 320, 20
Glioblastoma patients, Human
glioblastoma cell
Diagnostic information and aid in thera-
peutic decisions for cancer patients
Skog et al. (2008)
miR-214, 140, 147, 135b, 205, 150, 149, 370,
206, 197, 634, 485-5p, 612, 608, 202, 373,
324-3p, 103, 593, 574, 483, 527, 603, 649,
18a, 595, 193b, 642, 557, 801, let-7e
Patient with ovarian disease; primary
ovarian tumor cell
Diagnostic biomarkers Taylor and Gercel-Taylor
(2008)
Aberrant expression of exosomal miRNAs has been found under different pathological conditions, indicating that miRNAs could be potential biomarkers and thera-
peutic targets.This table describes exosomal miRNAs identiﬁed under different pathological conditions and their potential pathological signiﬁcance. FF, follicular ﬂuid;
HCC, hepatocellular carcinoma; PBMC, peripheral blood mononuclear cells; MDM, human monocyte-derived macrophage.
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Exosomes can shuttle mRNAs and miRNAs directly to recipi-
ent cells which increases the likelihood that this information will
alter the function of target cells. The release of exosomes allows
cell–cell communication regardless of the distance between the
cells. Exosomes have been identiﬁed in body ﬂuids and blood,
indicating that this exchange of information between organs
may occur via exosomes (Qazi et al., 2010). Additionally, exo-
somes may contain cell-speciﬁc factors that allow the exosomes to
target speciﬁc cells for delivery of the exosomal contents (pro-
teins, mRNAs, miRNAs, and DNAs) to recipient cells with a
high degree of efﬁciency. Exosomal miRNAs may reﬂect disease
speciﬁc-aberrations. Emerging evidence supports the hypothesis
that disease diagnosis can occur by examining levels of miRNA in
exosomes isolated from body ﬂuids. Finally, manipulation of the
miRNAs within exosomes may provide an effective tool to target
therapy to speciﬁc cells and organs.
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